Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of “Hold” from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been given an average rating of “Hold” by the seven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $10.80.

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research report on Monday, March 2nd. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS opened at $6.19 on Tuesday. The firm has a market cap of $1.07 billion, a PE ratio of 103.17 and a beta of 0.85. The firm’s 50 day simple moving average is $5.96 and its 200-day simple moving average is $6.74. Xeris Biopharma has a one year low of $4.30 and a one year high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, equities analysts predict that Xeris Biopharma will post 0.12 EPS for the current year.

Insider Buying and Selling

In other news, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $6.25, for a total transaction of $104,168.75. Following the transaction, the insider directly owned 1,226,507 shares of the company’s stock, valued at approximately $7,665,668.75. This trade represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director James Aloysius Brady sold 10,834 shares of Xeris Biopharma stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $5.54, for a total transaction of $60,020.36. Following the transaction, the director directly owned 89,166 shares in the company, valued at approximately $493,979.64. The trade was a 10.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 60,835 shares of company stock worth $367,860. Corporate insiders own 6.47% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new position in Xeris Biopharma during the fourth quarter valued at approximately $25,000. KBC Group NV acquired a new stake in Xeris Biopharma in the first quarter valued at approximately $27,000. AlphaQuest LLC acquired a new stake in Xeris Biopharma in the third quarter valued at approximately $35,000. Caitong International Asset Management Co. Ltd boosted its stake in Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.